Patents Assigned to Memorial Sloan-Kettering Cancer Center
  • Publication number: 20220370547
    Abstract: The present disclosure relates to novel lantibiotics, lantibiotic pharmaceutical compositions, isolated and recombinant lantibiotic-producing bacteria, bacterial pharmaceutical compositions, methods of producing novel lantibiotics from lantibiotic-producing bacteria, and methods of using such lantibiotics, lantibiotic pharmaceutical compositions, and bacterial pharmaceutical compositions to treat gram-positive bacteria infections, including vancomycin resistant enterococci infections, in patients, and to treat food and other objects to avoid gram-positive bacteria contamination.
    Type: Application
    Filed: December 28, 2021
    Publication date: November 24, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eric Pamer, Sohn Kim, Peter McKenney, Silvia Caballero
  • Patent number: 11505599
    Abstract: The presently disclosed subject matter provides antigen-binding proteins (e.g., chimeric antigen receptors) and antibodies or antigen-binding portions thereof that bind to a Foxp3 peptide/MHC molecule complex. Such antibodies, fusion proteins and conjugates thereof are useful for inhibiting regulatory T cells and treating cancers.
    Type: Grant
    Filed: January 13, 2017
    Date of Patent: November 22, 2022
    Assignees: MEMORIAL SLOAN-KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: David A. Scheinberg, Tao Dao, Cheng Liu
  • Publication number: 20220363775
    Abstract: The presently disclosed subject matter provides for chimeric receptors that target ADGRE2 and chimeric receptors that target CLEC12A. The presently disclosed subject matter also provides for cells comprising the ADGRE2-targeted chimeric receptors, cells comprising the CLEC12A-targeted chimeric receptors, and cells comprising the ADGRE2-targeted chimeric receptors and the CLEC12A-targeted chimeric receptors. The presently disclosed subject matter further provides uses of such cells for treating tumors, e.g., AML.
    Type: Application
    Filed: April 25, 2022
    Publication date: November 17, 2022
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, MILLENNIUM PHARMACEUTICALS, INC., SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES
    Inventors: Michel Sadelain, Sascha P. Haubner, Jorge Mansilla-Soto, Xingyue He, Gary Shapiro
  • Patent number: 11501434
    Abstract: Described herein are Deep Multi-Magnification Networks (DMMNs). The multi-class tissue segmentation architecture processes a set of patches from multiple magnifications to make more accurate predictions. For the supervised training, partial annotations may be used to reduce the burden of annotators. The segmentation architecture with multi-encoder, multi-decoder, and multi-concatenation outperforms other segmentation architectures on breast datasets, and can be used to facilitate pathologists' assessments of breast cancer in margin specimens.
    Type: Grant
    Filed: October 2, 2020
    Date of Patent: November 15, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Thomas Fuchs, David Joon Ho
  • Publication number: 20220356163
    Abstract: The present technology relates generally to compounds, compositions, and methods useful for treating, preventing, and/or ameliorating pathogenic cellular proliferation, angiogenesis, cancer, metastatic disease, and/or a pathogenic vascular proliferative disease in a subject.
    Type: Application
    Filed: September 30, 2020
    Publication date: November 10, 2022
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Robert BENEZRA, Ouathek OUERFELLI, Guangli YANG
  • Publication number: 20220339221
    Abstract: The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK?) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.
    Type: Application
    Filed: August 7, 2020
    Publication date: October 27, 2022
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Liang DENG, Stewart SHUMAN, Jedd WOLCHOK, Taha MERGHOUB, Weiyi WANG, Peihong DAI, Ning Yang
  • Publication number: 20220340557
    Abstract: The present disclosure provides compounds of Formula (I?), Formula (II), and Formula (III). The compounds described herein may useful in treating and/or preventing protozoan infections in a subject in need thereof, treating and/or preventing trypanosomal infections (e.g., Trypanosoma cruzi (T. cruzi) or Trypanosoma brucei infections) and/or plasmodial infections in a subject in need thereof, treating and/or preventing diseases in a subject in need thereof (e.g., Chagas disease, malaria, and/or sleeping sickness), and may be useful in treating and/or preventing infectious diseases in a subject in need thereof. Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including a compound described herein.
    Type: Application
    Filed: November 22, 2021
    Publication date: October 27, 2022
    Applicants: Memorial Sloan-Kettering Cancer Center, The Regents of the University of California, University of Central Florida Research Foundation, Inc., The Broad Institute, Inc.
    Inventors: Derek Shieh Tan, Corinne N. Foley, Gustavo Moura-Letts, James McKerrow, Sivaraman Dandapani, Rahul Edwankar, Alyssa Verano, Debopam Chakrabarti, Bracken Roberts
  • Patent number: 11471495
    Abstract: The present invention relates to methods and compositions for reducing the risk and severity of C. difficile infection. It is based, at least in part, on the discovery that a restricted fraction of the gut microbiota, including the bacterium Clostridium scindens, contributes substantially to resistance against C. difficile infection. Without being bound by any particular theory, it is believed that this is achieved through the biosynthesis of secondary bile acids.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: October 18, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Eric Pamer, Charlie Buffie, Peter McKenney
  • Patent number: 11472883
    Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.
    Type: Grant
    Filed: March 3, 2020
    Date of Patent: October 18, 2022
    Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.
    Inventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
  • Patent number: 11464874
    Abstract: The present invention relates to methods and compositions for inhibiting metastatic spread of cancer and/or inhibiting progression of pre-existing metastatic disease in a subject using L1CAM inhibition.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: October 11, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Karuna Ganesh, Manuel Valiente, Joan Massague
  • Patent number: 11464448
    Abstract: Described herein are systems and methods for image-based (e.g., MRI-based) spatial and temporal mapping of macrophages and other cell types, without the need for image contrast agents. These systems and methods are particularly useful for imaging macrophages because they naturally store metabolites, such as iron. Alternatively, the systems and methods described herein can be used where contrast agents are administered, rather than looking only at endogenous metabolite deposits.
    Type: Grant
    Filed: April 7, 2017
    Date of Patent: October 11, 2022
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Avigdor Leftin, Jason Koutcher
  • Publication number: 20220315660
    Abstract: The presently disclosed subject matter provides antibodies that bind to B-cell maturation antigen (BCMA) and methods of using the same.
    Type: Application
    Filed: February 11, 2021
    Publication date: October 6, 2022
    Applicants: MEMORIAL SLOAN KETTERING CANCER CENTER, EUREKA THERAPEUTICS, INC.
    Inventors: Renier J. Brentjens, Eric L. Smith, Chen Liu
  • Publication number: 20220313817
    Abstract: This invention provides methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, by administering a combination of at least one WT1 peptide, or cytotoxic T cells (CTLs) against a WT1-expressing cancer, and at least one checkpoint inhibitor. The at least one WT1 peptide can be administered to the subject by administering one or more agents to the subject resulting in delivery of one or more WT1 peptides and induction of an immune response against the WT1-expressing cancer. Examples of these WT1 delivery agents include: (i) an isolated WT1 peptide, (ii) a nucleic acid encoding the at least one WT1 peptide, and (iii) an immune cell comprising or presenting the at least one WT1 peptide or nucleic acid encoding the at least one WT1 peptide.
    Type: Application
    Filed: April 8, 2021
    Publication date: October 6, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventor: David A. SCHEINBERG
  • Patent number: 11458139
    Abstract: The present technology relates to compositions comprising BRAF inhibitors and uses thereof for treating and/or preventing a MEK inhibitor-associated cutaneous condition in a subject. Kits for use in practicing the methods are also provided.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: October 4, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Neal Rosen, Noa Shelach
  • Publication number: 20220307031
    Abstract: The presently disclosed subject matter relates to the administration of a KMT2D inhibitor for the treatment of a cancer. The present invention is based on the discovery that upon PI3K inhibition, KMT2D activity is upregulated, resulting in an increase in the expression of genes involved in breast cancer cell proliferation and tumor growth. Accordingly, the present invention provides methods for treating a subject that has cancer by administering a therapeutically effective amount of an KMT2D inhibitor.
    Type: Application
    Filed: February 10, 2022
    Publication date: September 29, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Jose Baselga, Eneda Toska, Scott Armstrong
  • Publication number: 20220306986
    Abstract: The present disclosure provides highly efficient, non-invasive, and reversible methods for selectively enriching pluripotent cells (e.g., human pluripotent cells and mouse pluripotent cells) in a cell population using a glutamine-deficient medium. The presently disclosed methods have the advantageous of efficiently enriching pluripotent cells in a heterogenous cell population without altering the biological properties of any individual cells.
    Type: Application
    Filed: October 29, 2021
    Publication date: September 29, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Lydia W.S. Finley, Craig B. Thompson, Santosha A. Vardhana
  • Patent number: 11453696
    Abstract: Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structures The compounds disclosed are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: September 27, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Minkui Luo, Xiaochuan Cai, Ke Wang, Junyi Wang
  • Patent number: 11453908
    Abstract: Disclosed herein are methods and compositions such as primers, primer pairs, and kits for typing KIR2DL1, KIR2DL2, Sand KIR2DL3 alleles. The compositions and methods disclosed herein are useful in the selection of most appropriate donors for HCT.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: September 27, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Katharine Hsu, Jean-Benoit Le Luduec
  • Publication number: 20220296177
    Abstract: The present invention, in one form, is a method for deriving respiratory gated PET image reconstruction from raw PET data. In reconstructing the respiratory gated images in accordance with the present invention, respiratory motion information derived from individual voxel signal fluctuations, is used in combination to create usable respiratory phase information. Employing this method allows the respiratory gated PET images to be reconstructed from PET data without the use of external hardware, and in a fully automated manner.
    Type: Application
    Filed: June 8, 2022
    Publication date: September 22, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventor: Adam L. Kesner
  • Publication number: 20220301098
    Abstract: Described are embodiments of a scalable system for processing whole slide images (WSIs). The system may heavily utilize parallel processing on both central processing units (CPUs) and graphics processing units (GPUs). Images may be decoded on a GPU. Reads may be unbuffered with a low memory footprint. Compute Unified Device Architecture (CUD A) operations may be employed to eliminate many inefficiencies in traditional WSI processing libraries.
    Type: Application
    Filed: May 6, 2020
    Publication date: September 22, 2022
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventor: Dig Vijay Kumar YARLAGADDA